ENDRA Life Sciences (NASDAQ:NDRA) versus Gadsden Properties (OTCMKTS:GADS) Critical Review

Gadsden Properties (OTCMKTS:GADS) and ENDRA Life Sciences (NASDAQ:NDRA) are both finance companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Volatility & Risk

Gadsden Properties has a beta of -5.57, indicating that its stock price is 657% less volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.

Earnings and Valuation

This table compares Gadsden Properties and ENDRA Life Sciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gadsden Properties	N/A	N/A	N/A	N/A	N/A
ENDRA Life Sciences	N/A	N/A	-$10.06 million	($901.15)	0.00

Analyst Ratings

This is a summary of recent recommendations and price targets for Gadsden Properties and ENDRA Life Sciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gadsden Properties	0	0	0	0	0.00
ENDRA Life Sciences	0	0	1	0	3.00

ENDRA Life Sciences has a consensus price target of $700,000.00, indicating a potential upside of 16,969,596.97%. Given ENDRA Life Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe ENDRA Life Sciences is more favorable than Gadsden Properties.

Institutional and Insider Ownership

1.2% of ENDRA Life Sciences shares are held by institutional investors. 5.0% of Gadsden Properties shares are held by insiders. Comparatively, 0.0% of ENDRA Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Gadsden Properties and ENDRA Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gadsden Properties	N/A	N/A	N/A
ENDRA Life Sciences	N/A	-127.39%	-103.77%

Summary

ENDRA Life Sciences beats Gadsden Properties on 5 of the 8 factors compared between the two stocks.

About Gadsden Properties

Gadsden Properties, Inc. is a Nevada corporation that was formed on December 28, 2010. Gadsden concentrates primarily on investments in high quality income-producing assets, residential developments and other opportunistic commercial properties in secondary and tertiary markets across the United States. The Company derives value from smaller, flexible retail investments that range from $5 million to $50 million and off-market mixed-use properties ranging from $50 million to $250 million. As a result of this chosen strategy, we believe that Gadsden is developing a unique competitive advantage that generally allows the Company to invest in markets and assets that are often overlooked by larger institutional investors, such as publicly-traded REITs and other large institutional investors. As part of its strategy, Gadsden attracts specific sellers that prefer the tax deferral advantages offered through issuing operating partnership units in exchange for their properties. These real estate assets are typically operated by independent owners that are seeking to monetize their real estate holdings, and who are typically not well capitalized or well-seasoned real estate operators. These transactions create a variety of outcomes for Gadsden and the sellers typically resulting in lease-up and value-added opportunities that may not be otherwise achieved.

About ENDRA Life Sciences

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.